The release of an important national notice will affect all arms companies

important notice from the National HealthOn December 25, the State Health Insurance Administration issued the Notice of the Office of the State Health Insurance Administration on Speeding Up the Implementation of the Medical Price and Credit Evaluation System, which showed that, in order to implement the Guidance of the State Health Insurance Administration on the Establishment of the Medical Price and Credit Evaluation System, relevant departments were required to fully understand the importance of the credit evaluation system.The evaluation system of pharmaceutical price and credit for recruitment is the basic system of centralized purchasing market for medicines and medical supplies, which is of great significance to regulate market behavior, purify the trading environment and protect the interests of the masses. Provincial medical security bureaus, pharmaceutical and medical supplies centralized procurement agencies should attach great importance to, fully understand the importance, urgency and difficulty of system construction, effectively enhance the sense of responsibility and mission, solidly promote all work, on time and quality implementation.The provincial medical security bureaus and centralized purchasing agencies are required to establish a system for evaluating pharmaceutical prices and credit by the end of 2020, formulate and issue relevant policy documents, and publish the List of Medical Prices and Confessions of Loss of Trust (2020 edition) on the official website of the Medical Security Bureau and on the centralized procurement platform.Each provincial centralized procurement agency as soon as possible to organize the province's bid hanging network enterprises as required to submit "pharmaceutical enterprise prices and marketing behavior credit commitment", to improve service awareness, online and offline parallel, convenient for pharmaceutical enterprises to submit trustworthy commitments, report related information.The above-mentioned notification also indicates that substantive progress should be made by the relevant bodies as soon as possible. In accordance with the principle of territory, the provincial centralized procurement agencies pay close attention to the local courts, taxation, market supervision and other departments open adjudication documents, administrative penalty decisions, especially the media focused on the typical cases, timely correspondence to investigate the enterprises involved, require enterprises to explain the situation, supplement the information required to deal with the case, if necessary, ask the relevant departments to give information support on the source of the case, in accordance with the requirements of the system, as soon as possible in the credit rating, graded disposal of substantive governance results.Prior to the national crackdown on resuming rebateson November 20th the State Health Insurance Administration issued the Code of Practice for the Evaluation of Pharmaceutical Prices and Credits (version 2020) (hereinafter referred to as the Code of Practice) to establish a system for evaluating pharmaceutical prices and credits for recruitment. Medical institutions purchase pharmaceutical products from honest enterprises, and reduce or suspend the procurement of pharmaceutical products from enterprises that fail to trust them.According to the Code of Practice, a list of credit evaluation catalogues will be established under the above-mentioned evaluation system, including the implementation of laws and regulations in the process of pricing, marketing, bidding and performance of pharmaceutical enterprises, acts contrary to good faith and fair competition for improper benefits, such as rebates or other improper benefits in the purchase and sale of medicines, the implementation of monopoly acts, price and tax-related violations, malicious breach of contract agreements, disruption of centralized procurement order, etc.

list includes seven specific items:1. "In the purchase and sale of medicines, rebates or other improper benefits shall be given to all types of medical institutions at all levels, centralized procurement agencies and their staffs".2. "Obtaining a false VAT invoice (except for a false VAT invoice in good faith)."3, "because of their own or related enterprises to implement monopoly agreements, abuse of market dominance, etc. were punished according to law, do not take the initiative to correct the unfair high prices of the products involved."4, "fabricated, spread price increase information, raise prices, promote excessive price increases and other violations of the Price Law."5, "pharmaceutical enterprises due to improper price behavior, by the pharmaceutical price authorities letter inquiry, investigation, interview, admonishment, inspection, etc., push, refuse, can not fully explain the reasons or make false commitments."6, belongs to the "bidding at a lower price than the cost, by fraud, bid rigging, abuse of market dominance and other ways to bid, disrupt the centralized procurement order."7. "Refusal to fulfill commitments, refusal to perform purchase and sale or distribution contracts without valid reasons".   On the same day, the State Health Insurance Administration also issued the "Pharmaceutical Price and Credit Rating Discretionary Benchmark (2020 Edition)", which clearly states that the price or marketing behavior of pharmaceutical enterprises in the same case cumulative or single bribe amount of more than 2 million yuan, or in the same case cumulative or single bribe amount of more than 2 million yuan, such as enterprises, the failure of trust rating is rated as "particularly serious."   For pharmaceutical enterprises rated as "particularly serious", in addition to warning and warning of risks, the enterprise should limit or suspend all drugs and medical supplies hanging network, bidding or distribution qualifications, limit or suspend the period according to the pharmaceutical enterprise credit repair behavior and results of timely adjustment. (Cypress Blue Equipment)